A Phase 1 interventional study of [14C] HDM1002 in Healthy Adult Subject, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.
Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, a single dose of [14C] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral [14C] HDM002.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of HDM1002 and \[14C\] HDM1002 administered orally.
Drug: [14C] HDM1002
Administered orally
Total recovery of HDM1002 radioactivity in urine and feces, following oral administration of [14C] HDM1002
Total recovery of radioactivity in urine and feces, and both routes combined expressed as a percentage of the total radioactive dose administered
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Metabolite profiling/identification in plasma, urine, and feces
Metabolic profiling/identification and determination of relative abundance of \[14C\]PF-06882961 and the metabolites of \[14C\] HDM1002 in plasma, urine, and feces.
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood AUC[0-t] of radioactivity
PK parameter : Area under the curve from time 0 to t hour
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood AUC[0-∞] of radioactivity
PK parameter : Area under the curve from time 0 hour to ∞
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood Cmax of radioactivity
PK parameter : Maximum observed concentration
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood Tmax of radioactivity
PK parameter : Time to maximum plasma concentration
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood t1/2 of radioactivity
PK parameter: Half life
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood CL/F of radioactivity
PK parameter : Apparent Clearance
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma and whole blood Vz/F of radioactivity
PK parameter : Apparent volume of distribution
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Percentage of plasma HDM1002 and metabolites in total plasma radioactivity
Percentage of plasma HDM1002 AUC in total plasma radioactivity AUC
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma AUC[0-t] of HDM1002 and metabolites
PK parameter : Area under the curve from time 0 to t hour
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma AUC[0-∞] of HDM1002 and metabolites
PK parameter : Area under the curve from time 0 hour to ∞
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma Cmax of HDM1002 and metabolites
PK parameter : Maximum observed concentration
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma Tmax of HDM1002 and metabolites
PK parameter : Time to maximum plasma concentration
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma t1/2 of HDM1002 and metabolites
PK parameter: Half life
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma CL/F of HDM1002 and metabolites
PK parameter : Apparent Clearance
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Plasma Vz/F of HDM1002 and metabolites
PK parameter : Apparent volume of distribution
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Adverse events (AEs)
Number of subjects reporting AEs
Time frame: Predose up to Day 11 after administration of [14C] HDM1002
Started Aug 2024 (actual). Primary completion is estimated for Oct 2024, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HDM1002
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. →